Skip to main content
Craig Tendler, MD, Pediatric Hematology & Oncology, Raritan, NJ

CraigLTendlerMD

Pediatric Hematology & Oncology • Raritan, NJ

Physician

Join to view full profile

Dr. Tendler is on Doximity

As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.

  • Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
  • Connect with colleagues in the same hospital or clinic.
  • Read the latest clinical news, personalized to your specialty.

See Dr. Tendler's full profile

Already have an account?

  • Office

    920 Route 202
    Raritan, NJ 08869
    Phone+1 908-927-4772

Education & Training

  • Icahn School of Medicine at Mount Sinai/Kravis Children's
    Icahn School of Medicine at Mount Sinai/Kravis Children'sFellowship, Pediatric Hematology/Oncology, 1991 - 1992
  • Icahn School of Medicine at Mount Sinai/Kravis Children's
    Icahn School of Medicine at Mount Sinai/Kravis Children'sResidency, Pediatrics, 1985 - 1988
  • Icahn School of Medicine at Mount Sinai
    Icahn School of Medicine at Mount SinaiClass of 1984

Certifications & Licensure

  • NJ State Medical License
    NJ State Medical License 1991 - 2025
  • NY State Medical License
    NY State Medical License 1985 - 2025
  • MD State Medical License
    MD State Medical License 1988 - 1991

Publications & Presentations

PubMed

Journal Articles

  • Predictors of Response to Anti‐IL6 Monoclonal Antibody Therapy (Siltuximab) in Idiopathic Multicentric Castleman Disease: Secondary Analyses of Phase II Clinical Trial...  
    David C Fajgenbaum, Craig Tendler, British Journal of Haematology

Abstracts/Posters

  • Quantitative Changes in Serum Proteins Including CXCL13 Are Early Indicators of Response to Anti-IL6 Therapy in Idiopathic Multicentric Castleman Disease
    Craig Tendler, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/7/2019

Press Mentions

  • Johnson & Johnson Files for U.S. FDA Approval of DARZALEX FASPRO®-Based Quadruplet Regimen for Newly Diagnosed Multiple Myeloma Patients for Whom Transplant Is Not Planned
    Johnson & Johnson Files for U.S. FDA Approval of DARZALEX FASPRO®-Based Quadruplet Regimen for Newly Diagnosed Multiple Myeloma Patients for Whom Transplant Is Not PlannedSeptember 30th, 2024
  • Update on IMBRUVICA® (Ibrutinib) U.S. Accelerated Approvals for Mantle Cell Lymphoma and Marginal Zone Lymphoma Indications
    Update on IMBRUVICA® (Ibrutinib) U.S. Accelerated Approvals for Mantle Cell Lymphoma and Marginal Zone Lymphoma IndicationsApril 6th, 2023
  • (Ibrutinib) as First and Only BTKi Treatment for Pediatric Patients with Chronic Graft-Versus-Host Disease
    (Ibrutinib) as First and Only BTKi Treatment for Pediatric Patients with Chronic Graft-Versus-Host DiseaseAugust 24th, 2022
  • Join now to see all

Dr. Craig Tendler, Dr. Craig Tendler, MD, Dr. C Tendler, Dr. Craig L Tendler